The mysterious onset of type 1 diabetes may have to do with what’s in your genes. Studies of twins show that if one twin has type 1 diabetes, the other has a 50 to 80 percent likelihood to also get the disease.
In the past 5 years, new technology that screens the whole genetic code allowed researchers to uncover at least 50 diabetes-associated genes. Interestingly, many of those genes also relate to other autoimmune diseases such as multiple sclerosis or celiac disease.
Stephan Kissler, Ph.D., Assistant Investigator in the Section on Immunobiology at Joslin Diabetes Center, studies those genes associated with multiple diseases using some of the newest lab techniques available. Video Rating: / 5
In observation of #WoundCareAwarenessMonth, infectious diseases specialist, Dr. Carlos Guerra, discusses diabetic wounds and prevention. Video Rating: / 5
What is diabetes mellitus? Diabetes mellitus is when there’s too much glucose, a type of sugar, in the blood. Diabetes mellitus can be split into type 1, type 2, as well as a couple other subtypes, including gestational diabetes and drug-induced diabetes. Find our full video library only on Osmosis: http://osms.it/more.
Join millions of current and future clinicians who learn by Osmosis, along with hundreds of universities around the world who partner with Osmosis from Elseiver to make medical and health education more engaging and efficient. We have unparalleled tools and materials to prepare you for success in school, on your board exams, and as a future clinician. Sign up for a free trial at http://osms.it/more. If you’re interested in exploring an institutional partnership, visit osmosis.org/educators to request a personalized demo.
Follow us on social:
Facebook: http://osms.it/facebook
Twitter: http://osms.it/twitter
Instagram for med: http://osms.it/instagram
Instagram for nursing: https://osms.it/ignursing
TikTok: https://osms.it/tiktok
Linkedin: https://osms.it/linkedin
Our Vision: Everyone who cares for someone will learn by Osmosis.
Our Mission: To empower the world’s clinicians and caregivers with the best learning experience possible. Learn more here: http://osms.it/mission
Medical disclaimer: Osmosis from Elsevier does not provide medical advice. Osmosis from Elsevier and the content available on the Osmosis from Elsevier properties (Osmosis.org, YouTube, and other channels) do not provide a diagnosis or other recommendation for treatment and are not a substitute for the professional judgment of a healthcare professional in diagnosis and treatment of any person or animal. The determination of the need for medical services and the types of healthcare to be provided to a patient are decisions that should be made only by a physician or other licensed healthcare provider. Always seek the advice of a physician or other qualified healthcare professional with any questions you have regarding a medical condition.
(Visit: http://www.uctv.tv) Cristina Brickman, MD. Assistant Professor of Medicine, Division of Infectious Disease, UCSF. Recorded on 04/08/2017. Series: “UCSF Vascular Surgery Symposium” [6/2017] [Professional Medical Education] [Show ID: 32301]
Type 1 diabetes is a genetic, auto-immune disorder. You can not “catch” diabetes from anyone. Lol. 😛 Video Rating: / 5
Developed and produced for http://www.MDPracticeGuide.com, a CME resource for physicians and healthcare providers.
Animation Description: Under normal circumstances, bacterial infection results in the release of chemokines that attract circulating neutrophils to the endothelium. This process is known as chemotaxis.
A variety of molecules are expressed on the endothelial cell surface that allow the neutrophil to be captured, then roll along the endothelium, then adhere.
Following adherence, the neutrophil migrates into the subendothelial tissue to reach the site of infection.
The neutrophil engulfs the bacteria and eliminates them via breakdown within the phagosomes — a process known as phagocytosis.
In states of hyperglycemia, chemotaxis is reduced. Adherence is also adversely affected.
Phagocytosis is also impaired by hyperglycemia.
Hyperglycemia also adversely affects the macrophage system. Under normal circumstances, circulating monocytes are attracted to sites of infection, roll, adhere, and then migrate into the subendothelial space. The monocyte then transforms into a macrophage.
which is then activated by cytokines released by the bacteria. The activated macrophage then engulfs the bacteria.
However, hyperglycemia results in decreased activation of macrophages, thereby arresting the process of macrophage phagocytosis of bacteria.
In addition to affecting neutrophil and macrophage function, hyperglycemia also affects the complement cascade. Under situations of normal glycemia, bacteria can activate the complement cascade.
Activation of the complement cascade results in the formation of transmembrane protein channels known as membrane attack complex (MAC) in bacterial membrane.
Membrane attack complexes make the bacterial membrane porous and the rapid influx of fluid results in the bacterial cell death.
Hyperglycemia inhibits the proper activation of the complement cascade, thereby reducing another pathway of the immune system.
To learn more visit: http://www.AnimatedDiabetesPatient.com
Presently in medicine, diabetes is not a curable disease. In type 1 diabetes, patients need lifelong insulin treatment to keep their blood sugars in normal range to avoid complications. In type 2 diabetes, studies suggest that in the very early stages of the disease it can be reversed with a strict calorie diet. But once type 2 diabetes is well established, it cannot be completely cured. Type 2 diabetes patients need to keep their blood sugars in normal range by maintaining a balanced diet, exercising regularly, and taking their medications on a regular basis to avoid long-term complications.
Grab your fun Diabetes T-shirts and bags from: https://diabeticdaduk.teemill.com/
This store is NOT FOR PROFIT. All orders benefit Diabetes charities and good causes. Video Rating: / 5
Immune diseases like type 1 diabetes and multiple sclerosis can lead to severe complications in patients, yet there are currently very limited treatment options which mitigate their impact at best and no opportunity for a cure. However, the discovery of a new technology platform at Belgium’s KU Leuven Hospital offers new hope for these patients.
Imotopes™ are modified HLA class II epitopes which block the immune processes that cause immune-mediated diseases, providing a potentially curative approach to severe chronic diseases. Imotopes™ induce cytolytic T cells that specifically eliminate antigen-presenting cells without affecting other functions of the immune system, intervening and stopping an autoimmune response at a time when attacked tissues can still regenerate.
Imotopes™ is the product of Imcyse, a clinical-stage biopharmaceutical company based in Lieges, Belgium, pioneering the development of this new class of active, specific immunotherapies. This technology is most advanced in the area of Type 1 Diabetes, with the development of IMCY-0098.
IMCY-0098 is a novel insulin-based Imotope™. In August 2019, Imcyse presented promising results from its first in human trial, a phase Ib safety study with IMCY-0098 in patients with early type 1 diabetes (T1D): IMCY-0098 is safe, well-tolerated, does not accelerate disease and is associated with immune modulation.
Imcyse is working with top clinicians at KU Leuven, as well as being part of INNODIA, a global partnership to fight Type 1 Diabetes. Through INNODIA’s Patient Advisory Committee Imcyse will ensure they deliver the treatment that Type 1 Diabetes patients want and need.
As clinical trials progress and basic research continues, the Imotope™ technology platform has the potential to address a wide range of indications in the vast field of immunology from diabetes to even less treatable conditions – with the potential to create a paradigm shift in the way these conditions are treated. Video Rating: / 5
